Welcome to our dedicated page for Tg Therapeutics news (Ticker: TGTX), a resource for investors and traders seeking the latest updates and insights on Tg Therapeutics stock.
TG Therapeutics Inc (NASDAQ: TGTX) is a biopharmaceutical innovator advancing therapies for B-cell malignancies and autoimmune disorders. This dedicated news hub provides investors and industry professionals with essential updates on clinical developments, regulatory milestones, and corporate strategies.
Access real-time announcements including trial results, FDA submissions, and partnership agreements. Our curated collection ensures you never miss critical updates about ublituximab (BRIUMVI), PI3K delta inhibitors, or emerging pipeline candidates.
Key content categories include quarterly earnings reports, scientific conference presentations, manufacturing updates. All materials are sourced directly from company filings and verified industry publications.
Bookmark this page for streamlined tracking of TGTX's progress in developing glycoengineered antibody therapies and maintaining compliance with financial disclosure requirements. Check regularly for authoritative updates on this NASDAQ-listed biotech pioneer.
TG Therapeutics (TGTX) plans to present data from the ULTIMATE I & II Phase 3 trials of BRIUMVI (ublituximab-xiiy) for treating relapsing forms of multiple sclerosis (RMS) at the American Academy of Neurology meeting from April 22-27, 2023. Key presentations include:
- Enhanced ADCC of Ublituximab on April 25.
- Efficacy in Treatment-Naive Participants on April 24.
- Subpopulation Analyses for Highly Active Disease on April 24.
The trials enrolled 1,094 patients across 10 countries and evaluated the drug's effectiveness against teriflunomide.
TG Therapeutics, Inc. (TGTX) announced its financial results for Q4 and full year 2022, highlighting a pivotal year with the FDA approval and launch of BRIUMVI for multiple sclerosis. Product revenue for 2022 was approximately $2.6 million, primarily from UKONIQ, which was withdrawn in May 2022. Research and development expenses decreased to $125.4 million from $222.6 million in 2021, while selling, general, and administrative expenses also fell to $70.0 million. The net loss narrowed to $198.3 million from $348.1 million in 2021. Cash reserves stood at $174.1 million, projected to fund operations into mid-2024.
TG Therapeutics will host a conference call on February 28, 2023, at 8:30 AM ET to discuss its 2022 fourth-quarter and year-end results and provide a business outlook for 2023. The call will be led by Michael S. Weiss, the company’s Chairman and CEO. Participants can join the call by dialing 1-877-407-8029 within the U.S. or 1-201-689-8029 from outside the U.S.
A live webcast will be available on TG Therapeutics' website, and a recording will be accessible for 30 days post-call. The company focuses on developing treatments for B-cell diseases and has received FDA approval for BRIUMVI™ for specific multiple sclerosis conditions.
TG Therapeutics (TGTX) announced the presentation of data from the ULTIMATE I & II Phase 3 trials of BRIUMVI™ (ublituximab-xiiy) for treating adult patients with relapsing multiple sclerosis at the 2023 ACTRIMS conference. The trials enrolled 1,094 patients across 10 countries, showcasing BRIUMVI's potential in managing RMS. CEO Michael S. Weiss expressed optimism about the data's implications for BRIUMVI's market position, which is now commercially available. The presentations included analyses on hematologic parameters and disease activity, reinforcing BRIUMVI's therapeutic attributes as TG Therapeutics aims to expand its market presence.
TG Therapeutics, Inc. (NASDAQ: TGTX) has announced the upcoming presentations of data from the ULTIMATE I & II Phase 3 trials of BRIUMVI™ (ublituximab) for relapsing forms of multiple sclerosis (RMS) at the ACTRIMS annual forum on February 23-25, 2023, in San Diego. These trials involved 1,094 patients treated over 96 weeks, comparing BRIUMVI to teriflunomide. Key presentations include findings on hematologic parameters and disease activity maintenance. BRIUMVI is a novel monoclonal antibody aimed at effectively managing RMS and has received FDA approval. Data from these presentations will be pivotal for investors and patients alike.
TG Therapeutics has launched BRIUMVI™ (ublituximab-xiiy), the first anti-CD20 monoclonal antibody approved for treating relapsing forms of multiple sclerosis (RMS) in adults. BRIUMVI requires only a one-hour infusion after the initial dose and is supported by a comprehensive patient assistance program. The drug's approval is based on positive results from the ULTIMATE I & II Phase 3 trials, demonstrating its effectiveness in significantly reducing the annualized relapse rate compared to teriflunomide. TG Therapeutics emphasizes its commitment to patient accessibility and support during treatment.
TG Therapeutics announced that CEO Michael S. Weiss will present at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023, at 9:45 AM PT. The event is hosted at the Westin St. Francis in San Francisco, CA. A live webcast of the presentation will be available on the Company's website. TG Therapeutics is focused on developing innovative therapies for B-cell diseases, with FDA approval for BRIUMVI™ for relapsing forms of multiple sclerosis.
TG Therapeutics announced the FDA approval of BRIUMVI (ublituximab-xiiy) for treating relapsing forms of multiple sclerosis in adults. This marks the first anti-CD20 monoclonal antibody approved for this indication, allowing for a biannual infusion schedule after a starting dose. Clinical trials ULTIMATE I & II demonstrated significant efficacy over teriflunomide by reducing the annualized relapse rate and lesion count. A commercial launch is anticipated in Q1 2023, with TG Therapeutics expressing commitment to patient access.
TG Therapeutics (TGTX) announced its Q3 2022 financial results, reporting a net loss of $35.8 million compared to $85.6 million in Q3 2021. R&D expenses decreased to $20.8 million from $52.0 million year-over-year, primarily due to cost-savings measures. SG&A expenses also fell to $14.3 million from $34.9 million. The FDA accepted the Biologics License Application for ublituximab, with a PDUFA goal date set for December 28, 2022. The company maintains a cash position of $197.7 million, sufficient to support operations into 2024.
TG Therapeutics (NASDAQ: TGTX) will host a conference call on November 10, 2022, at 8:30 AM ET to discuss its third-quarter 2022 results. The call will be led by Michael S. Weiss, Chairman and CEO. Interested parties can participate by calling 1-877-407-8029 (U.S.) or 1-201-689-8029 (international). A live webcast will be available on TG Therapeutics' website, and a recording will be accessible for up to 30 days post-call. The company focuses on developing treatments for B-cell diseases and has completed a Phase 3 program for ublituximab.
FAQ
What is the current stock price of Tg Therapeutics (TGTX)?
What is the market cap of Tg Therapeutics (TGTX)?
